S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
OTCMKTS:ATMS

Artemis Therapeutics (ATMS) Stock Forecast, Price & News

$0.22
0.00 (0.00%)
(As of 06/5/2023 ET)
Compare
Today's Range
$0.22
$0.22
50-Day Range
$0.17
$1.89
52-Week Range
$0.11
$5.00
Volume
N/A
Average Volume
2,942 shs
Market Capitalization
$24.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ATMS stock logo

About Artemis Therapeutics (OTCMKTS:ATMS) Stock

Artemis Therapeutics, Inc. is a biopharmaceutical company. It develops new treatments for serious and life-threatening infections. It Includes cytomegalovirus and malaria. The company was founded on April 22, 1997 and was headquartered in New York, NY.

Receive ATMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Artemis Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATMS Stock News Headlines

“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
Nasa reveals new spacesuit for Artemis moon landing
Artemis Therapeutics Inc. (ATMS)
“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
Artemis Therapeutics Inc
Nasa’s Artemis 1 moon mission explained
See More Headlines

ATMS Price History

ATMS Company Calendar

Today
6/05/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Miscellaneous chemical products
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ATMS
Employees
1
Year Founded
N/A

Profitability

Net Income
$-1,360,000.00
Net Margins
-299.54%
Pretax Margin
-299.54%

Debt

Sales & Book Value

Annual Sales
$310,000.00
Book Value
($0.01) per share

Miscellaneous

Free Float
103,687,000
Market Cap
$24.64 million
Optionable
Not Optionable
Beta
-1.92

Key Executives

  • Shimon Citron
    Chief Executive Officer & Director
  • Haim Tabak
    Chief Operating Officer
  • David Dana
    Chief Financial Officer
  • Dana Wolf
    Chief Medical Officer













ATMS Stock - Frequently Asked Questions

How have ATMS shares performed in 2023?

Artemis Therapeutics' stock was trading at $1.16 at the beginning of 2023. Since then, ATMS shares have decreased by 81.0% and is now trading at $0.2199.
View the best growth stocks for 2023 here
.

When is Artemis Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our ATMS earnings forecast
.

What is Artemis Therapeutics' stock symbol?

Artemis Therapeutics trades on the OTCMKTS under the ticker symbol "ATMS."

How do I buy shares of Artemis Therapeutics?

Shares of ATMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Artemis Therapeutics' stock price today?

One share of ATMS stock can currently be purchased for approximately $0.22.

How much money does Artemis Therapeutics make?

Artemis Therapeutics (OTCMKTS:ATMS) has a market capitalization of $24.64 million and generates $310,000.00 in revenue each year.

How can I contact Artemis Therapeutics?

Artemis Therapeutics' mailing address is 18 EAST 16TH STREET SUITE 307, NEW YORK NY, 10003. The official website for the company is www.artemis-therapeutics.com. The company can be reached via phone at (646) 233-1454, via email at ir@artemis-therapeutics.com, or via fax at 800-253-5177.

This page (OTCMKTS:ATMS) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -